Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
| ▸ | PDE8A | O60658 | 1/20 | 0.36 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401041 | 0.85 | CDK1 (0.65) | CDK1CCNB1CCNE1CDK2ADORA2B | |
| SCHEMBL4572145 | 0.82 | ADORA2A (0.56) | CDK1CCNB1CCNE1CDK2ADORA2B | |
| SCHEMBL3441186 | 0.82 | CDK1 (0.54) | CDK1CCNB1CCNE1CDK2PDE4D | |
| SCHEMBL179439 | 0.81 | PI4KA (0.57) | CDK1CCNB1CCNE1CDK2ADORA2B | |
| SCHEMBL14145054 | 0.80 | ADORA2A (0.58) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL19553535 | 0.79 | ADORA2A (0.53) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL15252931 | 0.78 | ADORA2A (0.64) | ADORA2BADORA2AADORA1 | |
| SCHEMBL15257782 | 0.77 | ADORA2B (0.48) | ADORA2BADORA2AADORA1 | |
| SCHEMBL3957296 | 0.76 | AHCY (0.66) | AHCYADORA2BADORA2AADORA1PI4KA | |
| SCHEMBL12417531 | 0.76 | CDK1 (0.58) | CDK1CCNB1CCNE1CDK2ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176858-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176858-A1 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADORA2A, ADORA1, ADORA2B | CDK1 1135/4885CCNB1 1699/4885CCNE1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.